close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

1,008.54 +20.45 (+2.07%)
Streaming Delayed Price Updated: 10:52 AM EDT, May 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Eli Lilly Just Announced Fantastic News for Shareholders ↗
Lilly's weight loss drugs have been delivering blockbuster revenue. 
Via The Motley Fool
Topics Earnings
News headline image
Ocular Therapeutix (OCUL) To Report Earnings Tomorrow: Here Is What To Expect
Ophthalmology biopharmaceutical company Ocular Therapeutix (NASDAQ:OCUL) will be announcing earnings results this Tuesday before the bell. Here’s what to loo... 
Via StockStory
News headline image
Pfizer Earnings: What To Look For From PFE
Global pharmaceutical company Pfizer (NYSE:PFE) will be reporting results this Tuesday before the bell. Here’s what investors should know. Pfizer beat analys... 
Via StockStory
News headline image
Jazz Pharmaceuticals (JAZZ) Q1 Earnings Report Preview: What To Look For
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) will be reporting results this Tuesday after market hours. Here’s what you need to know. Jazz Pharmaceut... 
Via StockStory
Topics Artificial Intelligence
Eli Lilly (NYSE:LLY) Shatters Q1 Expectations with Blowout Earnings Beat ↗
Via Chartmill
News headline image
Supernus Pharmaceuticals Earnings: What To Look For From SUPN
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) will be announcing earnings results this Tuesday after the bell. Here’s what to look ... 
Via StockStory
Topics Artificial Intelligence
News headline image
Why Eli Lilly Stock Jumped This Week ↗
A new weight loss pill is expanding the pharmaceutical leader's already massive market opportunity. 
Via The Motley Fool
News headline image
Pfizer Stock: Still Priced Like It's Dead Money ↗
Shares of Pfizer are down 50% from their 2021 high, and the yield is an alluring 6.4%. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Dear Veeva Systems Stock Fans, Mark Your Calendar for May 7
Veeva Systems stock pops following S&P 500 inclusion announcement. 
Via Barchart.com
Topics Earnings Stocks
News headline image
Deal Dispatch: Sirius XM Mulls Purchase Of iHeartMedia, Uber Buys FlyTaxi, Wren Kitchens Bankruptcy ↗
Major M&A deals this week include: Eli Lilly buys Profluent for $2.2 billion, Lazard buys Campbell Lutyens, FreshRealm bankruptcy. 
Via Benzinga
News headline image
Lilly's Double-Beat Widens the GLP-1 Gap—And a New Pill Could Make It Permanent ↗
Via MarketBeat
News headline image
There's Another Twist In The Obesity Pills Showdown — And This One Actually Helps Lilly ↗
The prescription data collected for Eli Lilly's new weight-loss pill, Foundayo, is flawed, analysts said Friday. 
Via Investor's Business Daily
News headline image
Why Eli Lilly (LLY) Stock Is Trading Up Today
What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 4.3% in the morning session after the stock continued to rally as the comp... 
Via StockStory
News headline image
Viking Therapeutics Faces Timeline Risk—But Upside Could Be Huge ↗
Via MarketBeat
News headline image
Eli Lilly Stock Popped on Earnings. America Can’t Get Enough of Its GLP-1s.
Eli Lilly stock jumps on strong Q1 performance numbers, with its GLP-1s leading the chart. 
Via Barchart.com
News headline image
Eli Lilly Capitalizes On Consumers' 'Love Affair' With Weight Loss Drugs: Gary Black Says Valuation 'Still Looks Compelling' ↗
Gary Black calls Eli Lilly's valuation 'compelling' as Q1 earnings soar, driven by the consumer 'love affair' with GLP-1 weight loss drugs. 
Via Benzinga
News headline image
LLY Q1 Deep Dive: Obesity Franchise Expansion and Pipeline Investment Drive Outperformance
Global pharmaceutical company Eli Lilly (NYSE:LLY) reported revenue ahead of Wall Street’s expectations in Q1 CY2026, with sales up 55.5% year on year to $19... 
Via StockStory
News headline image
Here's How Much $1000 Invested In Eli Lilly 15 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
GLP-1 Sales Continue to Lift Eli Lilly. Does That Make LLY Stock a Buy?
Eli Lilly stock rallies as GLP-1 sales drive a 56% year-on-year increase in Q1 revenue. Jim Cramer recommends buying LLY shares as the weight-loss addressable market is truly huge. 
Via Barchart.com
Thursday's session: top gainers and losers in the S&P500 index ↗
Via Chartmill
In today's session, there are S&P500 stocks with remarkable trading volume. ↗
Via Chartmill
Exploring the top movers within the S&P500 index during today's session. ↗
Via Chartmill
News headline image
Eli Lilly Raises 2026 Outlook On Strong Mounjaro And Zepbound Demand ↗
Eli Lilly beats Q1 estimates, lifts 2026 outlook as Mounjaro and Zepbound demand offsets pricing pressure and drives strong revenue growth. 
Via Benzinga
News headline image
Eli Lilly (LLY) Q1 2026 Earnings Transcript ↗
Eli Lilly (LLY) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Why Eli Lilly Stock Just Popped ↗
GLP-1 drugs turned Lilly into a powerhouse. Now it's time to write the next chapter -- in cancer. 
Via The Motley Fool
These S&P500 stocks are gapping in today's session ↗
Via Chartmill
News headline image
Eli Lilly Obliterates Sales Forecasts By $2 Billion, Shares Surge ↗
Eli Lilly stock popped early Thursday after the drugmaker crushed first-quarter sales forecasts and hiked its 2026 guidance. 
Via Investor's Business Daily
Discover the top S&P500 movers in Thursday's pre-market session. ↗
Via Chartmill
News headline image
Eli Lilly (NYSE:LLY) Delivers Strong Q1 CY2026 Numbers, Stock Soars
Global pharmaceutical company Eli Lilly (NYSE:LLY) reported Q1 CY2026 results topping the market’s revenue expectations, with sales up 55.5% year on year to ... 
Via StockStory
News headline image
What's the Next Big Thing After GLP-1 Drugs? CRISPR Therapeutics May Have the Answer. ↗
The biotech's candidate may treat a great number of illnesses that have one thing in common. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today